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Background: Pancreatic cancer, composed principally of pancreatic adenocarcinoma (PaC), is the fourth leading
cause of cancer death in the United States. PaC-associated diabetes may be a marker of early disease. We sought
to identify molecules associated with PaC and PaC with diabetes (PaC-DM) using a novel translational
bioinformatics approach. We identified fatty acid binding protein-1 (FABP-1) as one of several candidates. The
primary aim of this pilot study was to experimentally validate the predicted association between FABP-1 with PaC
and PaC with diabetes.
Methods: We searched public microarray measurements for genes that were specifically highly expressed in PaC.
We then filtered for proteins with known involvement in diabetes. Validation of FABP-1 was performed via
antibody immunohistochemistry on formalin-fixed paraffin embedded pancreatic tissue microarrays (FFPE TMA).
FFPE TMA were constructed using148 cores of pancreatic tissue from 134 patients collected between 1995 and
2002 from patients who underwent pancreatic surgery. Primary analysis was performed on 21 normal and 60
pancreatic adenocarcinoma samples, stratified for diabetes. Clinical data on samples was obtained via retrospective
chart review. Serial sections were cut per standard protocol. Antibody staining was graded by an experienced
pathologist on a scale of 0-3. Bivariate and multivariate analyses were conducted to assess FABP-1 staining and
clinical characteristics.
Results: Normal samples were significantly more likely to come from younger patients. PaC samples were
significantly more likely to stain for FABP-1, when FABP-1 staining was considered a binary variable. Compared to
normals, there was significantly increased staining in diabetic PaC samples (p = 0.004) and there was a trend
towards increased staining in the non-diabetic PaC group (p = 0.07). In logistic regression modeling, FABP-1
staining was significantly associated with diagnosis of PaC (OR 8.6 95% CI 1.1-68, p = 0.04), though age was a
confounder.
Conclusions: Compared to normal controls, there was a significant positive association between FABP-1 staining
and PaC on FFPE-TMA, strengthened by the presence of diabetes. Further studies with closely phenotyped patient
samples are required to understand the true relationship between FABP-1, PaC and PaC-associated diabetes.
A translational bioinformatics approach has potential to identify novel disease associations and potential
biomarkers in gastroenterology.
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Pancreatic cancer, composed principally of pancreatic
adenocarcinoma (PaC), is the fourth leading cause of
cancer death in the United States. At diagnosis, more
than 85% of patients with PaC have unresectable dis-
ease, with a median survival of 4-6 months [1,2].
PaC is a diabetogenic state with 45-65% of PaC
patients having diabetes mellitus (DM). New-onset DM,
occurring within approximately 2 years prior to cancer
diagnosis, may be a paraneoplastic effect of the tumor
itself secondary to a circulating tumor-associated protein
that causes insulin resistance and beta-cell dysfunction
[3]. Adult patients with new onset DM have an 8-fold
increased risk of developing PaC [4]. Given that this
PaC-associated DM often occurs when the cancer is
asymptomatic and resectable, it may be a useful marker
of early disease, though it is difficult to clinically distin-
guish from chronic type II diabetes mellitus [3].
Several strategies have been used to identify pancreatic
cancer-associated diabetogenic factors, including micro-
array work, genotyping, quantitative real time polymer-
ase chain reaction, immunohistochemistry, serum
analysis, gel electrophoresis and cell culture, and serum
radioimmunoassay. These have yielded putative biomar-
kers, including connexin-26, insulin gene promoter poly-
morphisms, glucagon/insulin ratio, S1000-A8 calcium
binding protein, islet amyloid polypeptide, and insulin-
like growth factor-I [5-10]. None have proven definitive.
The challenge is in identifying a molecule that is specifi-
cally upregulated in pancreatic adenocarcinoma that
simultaneously leads to diabetes.
We sought to identify molecules associated with PaC
and PaC with diabetes (PaC-DM) using an integrative
genomics approach, building from our previous methods
in intersecting publicly-available gene expression mea-
surements to find DNA variants associated with disease
[11,12]. We identified fatty acid binding protein-1
(FABP-1) as one of several candidate molecules. The
primary aim of this pilot study was to experimentally
validate the predicted association between FABP-1 and
PaC and PaC with diabetes.
Methods
Integrative Genomics
We have previously described the creation of a database of
gene expression microarray experiments across human
diseases, built from publicly-available repositories [13].
Specifically, gene expression microarray experiments in
the NCBI Gene Expression Omnibus (GEO) characteriz-
ing human disease conditions were automatically identi-
fied using a method where the Medical Subject Heading
(MeSH) terms attributed to publications associated with
GEO experiments are were evaluated for disease concepts
using the Unified Medical Language System (release
2007AC) [14,15]. Each of these experimental data sets
determined to be relevant to a human disease based on
associated MeSH disease concepts was subject to auto-
mated annotation of the disease condition, the tissue or
biological substance from which the samples were derived,
and whether or not the experiment measured a normal
control state complimentary to the annotated disease
state. The automated annotation step was performed
using a previously published method that analyzes particu-
lar annotations in a GEO DataSet, which is a higher-order
representation of an experiment in GEO that groups
experimental samples into logical subsets (e.g. “control”
and “treatment”) using a free-text vocabulary [16]. The
disease and tissue annotations were manually reviewed in
a post-processing step to ensure accuracy.
Our resulting data set incorporates over 200 diseases
studied across over 350 GEO datasets comprising nearly
ten thousand individual microarrays, studied in over 100
tissues. For every gene in the genome measured across
microarray platforms, we calculated a change in rank
normalized expression level in that gene from normal
samples to disease samples, resulting in a calculated
measure ranging from +1.0 (a gene changing from low-
est measured expression level in normal samples to
highest measured expression level in disease samples) to
-1.0 (a gene changing from highest measured expression
level in normal samples to lowest measured expression
level in disease samples).
Within this database of disease-related gene expression
changes, we searched for genes selectively upregulated in
pancreatic tissue from pancreatic adenocarcinoma, but
not in pancreatic tissue from samples with acute pancrea-
titis and type I diabetes mellitus; comparison groups were
limited to those conditions with robust available GEO
data.
Of those genes selectively fitting this profile, the rank
normalized expression level for the top ten genes ran-
ged from 0.19-0.12 with FABP-1 measuring 0.14, fifth
on the list.
We then compared this list of genes selectively upregu-
lated in pancreatic tissue from pancreatic adenocarci-
noma with that of genes known to be associated with
type II DM from the NIH Genetic Association Database
http://geneticassociationdb.nih.gov/. Type II DM sus-
ceptibility genes were compared given the similar pheno-
type in pancreatic cancer-associated diabetes of beta-cell
dysfunction and insulin resistance [17]. Type II diabetes
susceptibility genes were derived using the same bioinfor-
matics methods described above.
With a list of genes upregulated in both pancreatic
adenocarcinoma and type II DM, we then filtered for
a biofluid database containing proteins known to be
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from the Plasma Proteome Institute, the MAPU Pro-
teome database, and the Urinary Exosome database
[11,18-20]. We narrowed our search to proteins present
in serum/urine because of the likely necessity for a pro-
tein synthesized in the tumor to use the blood to reach
insulin target tissues, such as fat, muscle, and liver.
FABP-1 was thus chosen as a candidate for validation.
Selection of Cases and TMA
Formalin fixed paraffin embedded (FFPE) Tissue Micro-
arrays (TMA) were constructed using 148 cores of pan-
creatic tissue from 134 patients collected by the Stanford
University Department of Pathology between 1995 and
2002 from patients who underwent pancreatic surgery.
The FFPE TMA were constructed in 2004 using a man-
ual tissue arrayer (Beecher Instruments, Silver Spring,
Maryland, United States) following previously described
techniques using 1.0 mm cores [21]. The cores were
taken from areas in the paraffin block that were represen-
tative of the diagnostic tissue.
Figure 1 shows a flow diagram of samples included
and excluded from the analysis. Excluded were 67 sam-
ples, consisting of chronic pancreatitis (13), neuroendo-
crine tumors (11), metastatic cancer to pancreas (9),
ampullary adenocarcinoma (7), pancreatic cysts (5), cho-
langiocarcinoma (4), duodenal adenocarcinoma (3), and
osteoclast-like giant cell tumor (1).
Biopsies of normal pancreatic tissue are not routinely
obtained. Normal samples on our TMA were derived
from histologically normal cores obtained from an
organ that often also contained a pathologic pancreatic
condition. This is common practice in construction of
tissue microarrays [21-23]. In this way, many normal
tissues were “matched” to a given pancreatic disease
state. The TMA contained 14 normal samples matched
to pancreatic adenocarcinoma. In a matched analysis, it
is the discordant or differentially-staining pairs that are
informative for analysis. However, in our 14 normal/
pancreatic adenocarcinoma matched samples, only 4
were discordant for staining. We thus had inadequate
power to conduct a matched statistical analysis. We
consequently decided to compare FABP-1 staining
amongst “non-matched” samples: PaC samples and nor-
mal samples derived from an organ that did not also
contain pancreatic adenocarcinoma. Of the 21 normal
samples we used in our analysis, 5 were not matched to
any other pancreatic pathology. The other normal sam-
ples were matched to non PaC conditions: 8 normal/
neuroendocrine tumors, 2 normal/ampullary cancers,
1 normal/metastatic cancer to the pancreas, 4 normal/
pancreatic cysts, and 1 normal/cholangiocarcinoma. Pri-
mary analysis was performed on 21 normal and 60 pan-
creatic adenocarcinoma samples, stratified for diabetes.
IRB approval was obtained from the Stanford Research
Compliance Office, allowing retrospective collection of
patients’ age, gender, presence of diabetes, alcohol and
tobacco use. Clinical data was collected on a standar-
dized form by one physician-abstractor (RNS). Clinical
data was obtained from notes in a given patient’s chart.
Immunohistochemistry Staining and Scoring
Serial sections of 4 um were cut from the TMA blocks,
deparaffinized in xylene, and hydrated in a graded series
of alcohol. The slides were pretreated with EDTA pH9
buffers for FABP-1 in a microwave step. Immunohisto-
chemistry (IHC) staining was then performed using the
DAKO EnVision + System, Peroxidase (DAB), (DAKO,
Cambridgeshire, United Kingdom) for FABP-1 (1:20
dilution, Abcam, Cambridge, MA). Antibody staining
was graded by a single experienced pathologist per stan-
dard protocol on a scale of 0-3 (0 = no staining, 1+ =
1-25%, 2+ = 25-75%, 3+ = > 75%) based on the extent
of cytoplasmic staining in an individual histologic core
[22]. FABP-1 staining was interpreted as a binary vari-
able (0 or ≥ 1) as well as a FABP-1score (number
between 0-3).
Statistical Analyses
Patient data was reported using bivariate (c
2,F i s h e r s
Exact test, Wilcoxon Rank Sum with Bonferroni correc-
tion, and non parametric Kruskal-Wallis ANOVA) and
multivariate analyses (logistic regression with binary
outcome variables) to assess FABP-1 staining and clini-
cal characteristics. Statistical analyses were performed
using SAS Enterprise Guide 9.2 (Cary, NC).
Figure 1 Study flowchart.
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Overall, samples were from older patients who were
nondrinkers, half of whom were female, and half of
whom had smoking exposure. Twenty percent of sam-
ples were derived from diabetic patients.
Table 1 shows summary statistics for our tissue sam-
ple when divided into normal and PaC groups. In bivari-
ate analyses, normal samples were significantly more
likely to come from younger patients. There was a trend
toward normal samples being derived from patients with
less tobacco exposure.
Figure 2 reveals representative pancreatic adenocarci-
noma demonstrating no staining (upper left, 100x), 1+
staining (upper right 100x), 2+ staining (lower left,
100x), and 3+ staining (lower right, 200x) with FABP-1.
Table 2 describes our sample in terms of FABP-1
staining by normal tissue versus PaC. The majority of
samples in normal and PaC groups did not stain for
FABP-1. In bivariate analyses when FABP-1 staining was
considered a binary variable, PaC samples were signifi-
cantly more likely to stain for FABP-1. There was a
trend towards statistically increased staining of PaC
samples when FABP-1 staining was interpreted as a
four-level score.
In Table 3, FABP-1 staining was compared in normal
and PaC groups, stratified for diabetes. Only 3 normal
samples were derived from diabetic patients, and none
stained for FABP-1. Because stratification of normals
into diabetic/nondiabetic groups yielded no difference in
the analysis described, the decision was made to present
the normal samples as a single group of diabetics and
non-diabetics.
Because the data failed to meet assumptions of nor-
mality and homogeneity of variances, we performed
nonparametric Kruskal-Wallis ANOVA to compare
FABP-1 staining in normal, PaC without DM (PaC
no DM), and PaC with diabetes (PaC-DM) samples.
PaC-DM samples represent tissue from patients with
pancreatic adenocarcinoma-associated diabetes as well
as PaC with coexisting chronic type II diabetes. The
information to differentiate between these two groups
was not available during chart review. Nonparametric
analyses revealed a significant difference in FABP-1
staining (using both binary and FABP-1 score) between
samples from normal, PaC no DM, and PaC-DM
groups, with significantly increased staining as one
moves from left to right in the Table 3. The PaC-DM
group had the highest percentage of FABP-1 staining.
Only one normal sample stained positively for FABP-1.
There was no significant difference in age between sam-
ples from PaC no DM and PaC-DM groups that stained
for FABP-1.
To elucidate relationships between the three groups,
individual paired tests were conducted using the Wil-
coxon Rank sum test with Bonferroni correction for
multiple comparisons. There was significantly increased
staining in the PaC-DM samples compared to normals
(p = 0.004) and there was a trend towards significantly
increased staining in the PaC no DM group versus nor-
mal (p = 0.07). There was no statistical difference in
FABP-1 staining between PaC no DM and PaC-DM
groups (0.09).
In logistic regression modeling, FABP-1 staining (bin-
ary) was significant associated with diagnosis of PaC with
an odds ratio of 8.6 (95% CI 1.1-68, p = 0.004). Age was a
confounder in this model. Patient gender did not modify
the relationship between FABP-1 staining and diagnosis.
Discussion
Using methods in integrative genomics, we predicted an
association between FABP-1 and pancreatic adenocarci-
noma and pancreatic adenocarcinoma with diabetes.
Compared to normal controls, we found a significant
positive association between increased FABP-1 staining
and PaC on FFPE-TMA, strengthened by the presence
of diabetes.
FABP-1 is a cytosolic chaperone protein that is
expressed in the liver, kidney, lung, and GI tract [24].
The exact role of FABP-1 has yet to be elucidated. The
association of FABP-1 with pancreatic adenocarcinoma
and diabetes is of interest. Plausibility of FABP-1 as bio-
marker for cancer comes from previous literature sug-
gesting an association with colon, gastric, and liver
cancers. The literature is variable, but loss of FABP-1
expression in colonic tissue has correlated with progres-
sion from normal colonic tissue to adenoma to carci-
noma [25]. Negative FABP-1 expression in colon cancer
metastases has been associated with decreased survival,
and low FABP-1 expression in colon cancer has been
associated with lymph node metastasis [26,27]. FABP-1
gene expression has been identified as a marker of cir-
culating colorectal tumor cells via RT-PCR [28]. On the
Table 1 Summary Statistics for sample
a
Characteristic Normal Tissue
b PaC
c p
d
Age 59 (26-79) 64.5 (45-79) 0.007
Female 13 (62%) 28 (47%) 0.22
History of Tobacco Use 5 (28%) 27 (57%) 0.051
History of Alcohol Use 5 (28%) 20 (42.6%) 0.39
Diabetes Mellitus 3 (17%) 10 (21%) 1.00
aTable values are n (column %) except for age which is represented as
median (range). Statistical significance was taken to be p≤ 0.05.
bN = 21 for age and female characteristics, n = 18 for tobacco/alcohol/
diabetes due to missing data. Column percentages will not sum to 100%.
cN = 60 for age and female characteristics, n = 47 for tobacco/alcohol/
diabetes due to missing data.
Column percentages will not sum to 100%.
dp-value calculated via Wilcoxon Rank-Sum (age), Chi square (female), or
Fishers exact tests (Tobacco, Alcohol, Diabetes).
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colon cancer with increased survival [29]. FABP-1 is
highly expressed in gastric intestinal metaplasia and a
subset of gastric adenocarcinoma [30]. In one study, half
of 62 hepatocellular carcinoma samples contained
L-FABP immunoreactive tumor cells [31]. A single
study of gene array analysis in a cohort of 21 patients
revealed FABP-1 overexpression (16x) in PaC compared
to chronic pancreatitis and normal pancreatic tissue,
though no further testing was performed to validate this
association [5]. Another group using bioinformatics
methods also identified FABP-1 as a candidate molecule
potentially associated with PaC, though again, no further
validation was performed [32].
Plausibility of FABP-1 as a biomarker for diabetes
comes from animal and human data. FABP-1 null mice
demonstrate age dependent weight gain, though may be
protected from obesity and hepatic steatosis when fed a
saturated fat diet [33-36]. In humans, high levels of
FABP-1 in placental homogenates have been associated
with gestational DM [37]. Two genes with variants lead-
ing to Maturity Onset Diabetes of the Young (MODY),
Hepatic nuclear factor (HNF)-4alpha and HNF-1alpha,
are known to directly bind to the promoter region of
FABP-1 [38]. Effects of FABP-1 are modulated through
PPAR-gamma, the molecular target for the thiazolidine-
dione class of diabetic medications [39]. In humans,
FABP-1 polymorphisms have been associated with
increased levels of fasting triglycerides/LDL in females
and urinary FABP-1 excretion is associated with hyper-
tension and coronary artery disease risk factors [40,41].
With its up-regulation in various forms of cancer and
effects on metabolism, it is plausible that FABP-1 could
be a biomarker for pancreatic cancer and pancreatic
cancer-associated diabetes.
Figure 2 FABP-1 Immunohistochemistry Staining Graded from 0-3.
Table 2 Description of the Sample by Normal Tissue vs.
Pancreatic Adenocarcinoma
a
Characteristic Normal Tissue
b PaC
c p
d
FABP-1 positive
e 1 (5%) 18 (30%) 0.02
FABP-1 Score 0.059
0: Negative 20 (95%) 42 (70%)
1: 1-25% 0 (0%) 12 (20%)
2: 25-75% 1 (5%) 5 (8%)
3: > 75% 0 (0%) 1 (2%)
aTable values are n (column %).
bN = 21.
cN = 60.
dp values represent Fisher’s exact test.
eFABP-1 positive defined as FABP-1 score ≥ 1.
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validate the FABP-1 association for PaC and PaC with
DM. The intent of our study was to examine whether a
computational approach could identify proteins asso-
ciated with a particular disease, as a preliminary step in
biomarker discovery. As mentioned, we narrowed our
search to proteins present in serum/urine because of the
postulated presence of a circulating diabetogenic factor
that exerts peripheral effects. Also, a diagnostic test
would necessarily be a serum/urine assay.
Of note, FABP-1 has been in detected in animal and
human serum/urine and commercial ELISA-kits are
available for FABP-1 serum/urine detection [42-47].
Possible mechanisms for FABP-1 presence in the serum
could involve cell lysis or cellular secretion. The discov-
ery of a biomarker for PaC-associated DM would be of
immense value for the early detection and treatment of
PaC. Association by immunohistochemistry alone, how-
ever, does not necessarily translate to diagnostic utility
nor causality. We have no evidence to prove that FABP-
1 is responsible for the pathogenesis of diabetes. Future
experiments will involve larger sets of both pathologic
and serum samples, with closely phenotyped patient
samples to further explore this association.
Global gene expression analysis in patients with PaC-
associated DM is a complimentary and contributory
approach to biomarker discovery using integrative
bioinformatics. Gene expression analysis could confirm
the FABP-1 overexpression we predict. There is no
published literature that specifically investigates
the gene expression of tumor tissue in PaC-associated
D M .F u t u r ew o r kw i l lb ei m p o r t a n tt of i l lt h a tk n o w l -
edge gap.
There are several limitations of our study. When con-
sidered a binary variable, FABP-1 staining was defined
as a score ≥ 1. A more stringent cutoff for FABP-1
staining would change our reported associated with pan-
creatic cancer. However, we do feel that in this pilot
study, grouping pancreatic cancer groups by the pre-
sence or absence of FABP-1 staining was reasonable,
given that only one normal sample stained positive for
FABP-1 and that the degree of FABP-1 expression is
likely to vary between tumors. The extent of FABP-1
staining will be explored in future studies with more
patients samples that are better phenotyped. In multi-
variate analyses, age was noted to be a confounder of
FABP-1 staining, though it should again be noted that
only one sample in the normal group stained with
FABP-1 and this sample was from a patient that was
younger than the average age of the staining population
in the PaC group. Rather than a true confounder, the
association between age and FABP-1 staining may be a
result of selection bias from our convenience sample or
a spurious association. Larger studies are needed to
further explore this relationship.
There are limitations of the bioinformatics technique
itself, including potential low specificity for a given bio-
marker, the assumption that differential gene expression
is necessarily reflected in plasma or urine, and that we
excluded proteins currently not known to be detectable
in serum or urine. Biomarker discovery using this meth-
odology is necessarily limited by quantity, quality, and
availability of public microarray datasets for a disease.
However, it should be noted that these limitations have
not precluded successful discovery of biomarkers for
other diseases [12].
Our data collection was retrospective and subject to
idiosyncrasies in chart documentation. We could not
differentiate pancreatic cancer-associated diabetes from
pancreatic cancer coexisting with chronic diabetes. The
PaC-DM group presented represents true PaC-
associated DM cases as well as those in whom the DM
was unrelated to PaC, in unknown proportions. This
distinction can be elucidated in future serum FABP-1
studies with more detailed available clinical information.
Our sample was a nonrandom small convenience sam-
ple, which likely contributed to the lower than published
prevalence of diabetes in PaC, the age difference between
normal and cancer groups, and the fact that we were not
adequately powered to run a matched analysis [3]. How-
ever, one would expect nondifferential misclassification
and a small sample size to skew results towards the null.
Table 3 Description of the Sample by Normal Tissue vs. PaC with and without Diabetes
a
Characteristic Normal Tissue (n = 21) PaC no DM (n = 37) PaC-DM (n = 10) p
b
FABP-1 positive
c 1 (5%) 9 (24%) 5 (50%) 0.02
FABP-1 Score 0.02
0: Negative 20 (95%) 28 (76%) 5 (50%)
1: 1-25% 0 (0%) 7 (19%) 3 (30%)
2: 25-75% 1 (5%) 2 (5%) 1 (10%)
3: > 75% 0 (0%) 0 (0%) 1 (10%)
aTable values are n (column %). Due to missing data on diabetes status, the total number of patients in the PaC group was n = 47. PaC-DM represent samples
from patients with pancreatic adenocarcinoma and diabetes. It was not possible to differentiate new-onset diabetics from chronic diabetics.
bp values represent Nonparametric Kruskal-Wallis ANOVA.
cFABP-1 positive defined as FABP-1 score ≥ 1.
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staining PaC and PaC with diabetes was found suggests
that the true association is stronger. It would have been
informative have more normal samples from diabetics to
confirm lack of FABP-1 staining.
Finally, our normal samples were representative of histo-
logically normal tissue that often did come from organs
that had pancreatic pathology. We cannot rule out con-
cerns of tumor microenvironment, though it should be
noted that histologic normalcy is the basis for adequate
surgical margins during tumor resection, and that this
technique is standard practice in construction of microar-
rays and has yielded reproducible results for other types of
cancer/normal tissue [22,23]. Future studies will use a con-
trol group of patients without pancreatic disease. Only one
pathologist scored immunohistochemistry; however, he
has several years experience. Our study would have been
strengthened by having at least two independent patholo-
gists read and score FABP-1 staining.
Conclusions
In conclusion, our study was proof of concept that a
translational bioinformatics approach has potential to
identify novel disease associations in gastroenterology.
Further experimental and clinical research is required to
understand the true relationship between FABP-1, pan-
creatic cancer, and PaC-associated DM.
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